MS 275

Product Description

MS 275 is a class I HDAC inhibitor (IC₅₀ values are 0.18, 0.74, 44.9 and >100 μM for HDAC1, 3, 8 and 6, respectively). Exhibits antiproliferative effects and induces apoptosis in a range of tumor cell lines in vitro and in vivo. Increases estrogen receptor α- and aromatase expression in breast cancer cells. Inhibits PCB-induced neuronal cell death by preventing HDAC3 binding and histone deacetylation within the synapsin-1 promoter.

Solubility

Preparing Stock Solutions for MS 275

The following data is based on the product molecular weight 376.41

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.66 mL	13.28 mL	26.57 mL
5 mM	0.53 mL	2.66 mL	5.31 mL
10 mM	0.27 mL	1.33 mL	2.66 mL
50 mM	0.05 mL	0.27 mL	0.53 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Sabnis Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letr. Cancer Res. 2011 PMID: 21245100
• Beckers Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int.J.Cancer 2007 PMID: 17455259
• Formisano MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter. J.Pharmacol.Exp.Ther. 2015 PMID: 25467131
• Saito A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc.Natl.Acad.Sci. 1999 PMID: 10200307